Company

Bank

Analyst

Coverage

Opinion

Wk chg

11/2 cls

Charles River Laboratories International Inc. (NYSE:CRL)

Jefferies

David Windley

Price target

Hold

0%

$39.44

Windley raised his target to $44 from $35 after Charles River reported 3Q12 EPS of $0.65, beating the $0.62 consensus estimate (see "EPS Watch," A22). In October, AstraZeneca plc (LSE:AZN; NYSE:AZN) named the tool supplier as its preferred outsourcing partner for regulated safety assessments and drug metabolism and pharmacokinetic development into 2015. Windley believes the deal will help increase the performance of Charles River's research models segment. He raised his EPS estimates to $2.73 from $2.72 in 2012 and to $3.09 from $2.97 in 2013.